Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Crinetics Pharmaceuticals, Inc. - Common Stock (NQ:CRNX)

36.53 +0.62 (+1.73%)
Streaming Delayed Price Updated: 2:01 PM EDT, Jun 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Crinetics Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
News headline image
Hedge Fund Drops $37 Million on Rare Disease Biotech Crinetics. Is It a Buy? ↗
Crinetics Pharmaceuticals develops oral therapies for rare endocrine diseases. 
Via The Motley Fool
Topics ETFs Regulatory Compliance
News headline image
Crinetics (CRNX) Q1 2026 Earnings Transcript ↗
Crinetics (CRNX) Q1 2026 Earnings Transcript 
Via The Motley Fool
Crinetics Pharmaceuticals (NASDAQ:CRNX) Beats Q1 Expectations on Strong PALSONIFY Launch, Stock Slips After Hours ↗
Via Chartmill
News headline image
Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More ↗
This biotech specializing in endocrine therapies reported a notable insider sale as it advances clinical-stage drug candidates. 
Via The Motley Fool
Topics Regulatory Compliance
Crinetics Pharmaceuticals (NASDAQ:CRNX) Beats Q4 Revenue Estimates on First Product Sales ↗
Via Chartmill
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial ↗
Via Stocktwits
News headline image
This Fund Has a $200 Million Bet on a Biotech Stock Up 30% in Days After Phase 3 Breakthrough ↗
This biotech specializes in therapies for neurological disorders, advancing a diverse pipeline through late-stage trials and collaborations. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Battery Storage Stock Up 50% in a Year Draws New $110M Investment. Here's What You Should Know ↗
This energy storage firm develops battery solutions for utility and commercial clients, targeting grid-scale renewable energy markets. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Biotech Stock Up 685% Draws $80.5 Million Investment Amid Dual FDA Filings ↗
Praxis Precision Medicines focuses on clinical-stage therapies for central nervous system disorders, targeting unmet needs in neurology. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Earnings Scheduled For November 6, 2025 ↗
 
Via Benzinga
Retail Chatter Surges As Crinetics Wins FDA Nod For First Oral Acromegaly Drug — Traders Expect Big Price Move ↗
Via Stocktwits
News headline image
Crinetics (CRNX) Q4 2025 Earnings Call Transcript ↗
Crinetics (CRNX) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Corcept Therapeutics (CORT): A Deep Dive into the 43.7% Earnings Growth and the High-Stakes Pivot to Oncology
As of January 28, 2026, Corcept Therapeutics (NASDAQ: CORT) stands at a critical crossroads that perfectly encapsulates the high-stakes nature of the biotechnology sector. Once a niche player focused... 
Via Finterra
Topics Economy Intellectual Property
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
Wondering what's happening in today's pre-market session? ↗
Via Chartmill
News headline image
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year ↗
Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why Crinetics Pharmaceuticals Stock Was Sliding on Friday ↗
The company is preparing a rollout of its recently FDA-approved acromegaly treatment. 
Via The Motley Fool
News headline image
Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) Emerges as a Technical Breakout Candidate ↗
Crinetics Pharmaceuticals (CRNX) shows strong technical momentum and a high-quality consolidation setup, signaling a potential breakout opportunity for traders. 
Via Chartmill
News headline image
Crinetics Pharmaceuticals (NASDAQ:CRNX) Reports Q3 2025 Earnings Miss ↗
Crinetics Q3 2025 earnings miss estimates as it transitions to a commercial-stage company following the U.S. launch of its new drug, PALSONIFY. 
Via Chartmill
Topics Earnings
News headline image
Fastenal Posts Downbeat Earnings, Joins Vince Holding And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Is Crinetics Pharmaceuticals Stock a Buy? ↗
The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success. 
Via The Motley Fool
News headline image
FDA Approves Crinetics Pharma's First Daily Pill For Rare Growth Disorder ↗
On Thursday, the U.S. 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Friday's Intraday Session ↗
Gainers Indaptus Therapeutics (NASDAQ: INDP) stock moved upwards by 108.1% to $6.83 during Friday's regular session. The market value of their outstanding shares is at $3.6 million. 
Via Benzinga
News headline image
Friday's session: gap up and gap down stocks ↗
Let's have a look at the gap up and gap down stocks in today's session. 
Via Chartmill
News headline image
Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA... 
Via Benzinga
Topics Stocks
News headline image
Assessing Crinetics Pharmaceuticals: Insights From 4 Financial Analysts ↗
Throughout the last three months, 4 analysts have evaluated Crinetics Pharmaceuticals (NASDAQ: CRNX), offering a diverse set of opinions from bullish to bearish. Summarizing their recent assessments,... 
Via Benzinga
News headline image
Crinetics Pharma Surges After FDA OKs Its Treatment For A Form Of Gigantism ↗
The company's drug, Palsonify, treats acromegaly, a condition in which the pituitary gland makes too much growth hormone. 
Via Investor's Business Daily
Topics Artificial Intelligence
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
Gainers bioAffinity Technologies (NASDAQ: BIAF) stock increased by 71.8% to $5.86 during Friday's pre-market session. The company's market cap stands at $4.5 million. 
Via Benzinga
News headline image
Tuesday's pre-market session: top gainers and losers ↗
Before the US market kicks off on Tuesday, let's examine the pre-market session and unveil the notable performers among the top gainers and losers. 
Via Chartmill
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.